Comparison 2. Doxycycline plus rifampicin (DR) versus quinolones plus rifampicin (QR).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Total treatment failure	5		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
1.1 Follow up duration less than 6 months	5	333	Risk Ratio (M‐H, Fixed, 95% CI)	1.41 [0.87, 2.28]
1.2 Follow up duration more than 6 months	3	181	Risk Ratio (M‐H, Fixed, 95% CI)	0.94 [0.45, 1.98]
2 Relapse	5		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
2.1 Follow up duration less than 6 months	4	247	Risk Ratio (M‐H, Fixed, 95% CI)	1.24 [0.59, 2.61]
2.2 Follow up duration more than 6 months	3	181	Risk Ratio (M‐H, Fixed, 95% CI)	0.95 [0.40, 2.27]
3 Persistence of symptoms	3	267	Risk Ratio (M‐H, Fixed, 95% CI)	1.80 [0.72, 4.53]
4 Adverse drug reactions	4		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
4.1 Severe (drug regimen changed)	1	86	Risk Ratio (M‐H, Random, 95% CI)	1.82 [0.17, 19.35]
4.2 Minor (drug regimen did not change)	4	296	Risk Ratio (M‐H, Random, 95% CI)	1.80 [0.78, 4.18]
4.3 All adverse reactions	4	296	Risk Ratio (M‐H, Random, 95% CI)	1.79 [0.79, 4.07]
5 Time to defervescence (days)	2	69	Mean Difference (IV, Fixed, 95% CI)	1.20 [0.55, 1.85]